Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
product photo
product photo
THIS DEVICE IS COMMERCIALLY AVAILABLE FOR USE IN SELECTED INTERNATIONAL MARKETS.
OVERVIEW
DETAILS
EVIDENCE

BUILD A LEGACY OF SUPERIOR HEART FAILURE OUTCOMES*,1

How your patients live their lives depends on the LVAD you choose. HeartMate 3™ LVAD with Full MagLev™ Flow Technology delivers outstanding survival and safety outcomes as demonstrated in the MOMENTUM 3 Trial at 2 years.*,1 With the HeartMate 3 LVAD, you can go above and beyond to make a meaningful difference in patient lives.

THE HIGHEST PUBLISHED 2-YEAR SURVIVAL RATE AND THE LOWEST PUBLISHED STROKE AND THROMBOSIS RATES FOR CONTINUOUS-FLOW LVADS**,***,1-5
 

 

Read more about the Clinical Evidence for HeartMate 3 LVAD.

COMPREHENSIVE HEART FAILURE MANAGEMENT

The HeartMate 3™ LVAD is part of our heart failure management portfolio. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.

REFERENCES

* HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
** For a continuous-flow LVAD in a randomized controlled trial.
*** Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
1. 1. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. The New England journal of medicine. 2019;380:1618-1627. doi:10.1056/NEJMoa1900486.
2. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, ... Gregoric ID. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-460.
3. Starling RC, Estep JD, Horstmanshof DA, et al; ROADMAP Study Investigators (2017). Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. J Am Coll Cardio HF. 2017;5:518-27.
4. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardio. 2014;63:1751-7.
5. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.

OPTIMIZING OUTCOMES THROUGH MEANINGFUL INNOVATION

The HeartMate 3™ LVAD system is comprised of the HeartMate 3 LVAD pump, a wearable external battery pack, the driveline, a pocket-sized controller and the mobile power unit (MPU).

OUTCOMES MADE POSSIBLE BY FULL MAGLEV™ FLOW TECHNOLOGY

Full MagLev™ Flow Technology maintains gentle blood handling to minimize complications and reduce hemocompatibility-related adverse events.

  • Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways to reduce shear stress1
  • Intrinsic pulsatility to reduce stasis and minimize thrombus1,2
OTHER HEARTMATE 3 LVAD FEATURES AND BENEFITS:
  • Offers up to 17 hours of battery life for greater patient confidence and convenience
  • Designed for intrapericardial placement
  • Features a thin, mechanical apical cuff lock for pump attachment
  • Incorporates a modular driveline that facilitates replacement of externalized portion
COMPREHENSIVE HEART FAILURE MANAGEMENT

The HeartMate 3™ LVAD is part of our heart failure management portfolio. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.

REFERENCES
  1. Bourque K, Cotter C, Dague C, et al. Design Rationale and Preclinical Evaluation of the HeartMate 3 Left Ventricular Assist System for Hemocompatibility. American Society of Artificial Internal Organs. 2016;62:375–383.
  2. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.

HEARTMATE 3™ LVAD DELIVERS OUTSTANDING SURVIVAL AND SAFETY OUTCOMES AT 2 YEARS*,1

THE HIGHEST PUBLISHED 2-YEAR SURVIVAL RATE AND THE LOWEST PUBLISHED STROKE AND THROMBOSIS RATES FOR CONTINUOUS-FLOW LVADS1-5, **, ***
 

HeartMate 3 LVAD outcomes made possible by Full MagLev™ Flow Technology.

HEARTMATE 3 LVAD MAKES A REAL DIFFERENCE IN PATIENT LIVES

Significant improvement in NYHA Class, 6-minute walk distance and quality of life1

More than 79% of patients improved to NYHA Class I/II from NYHA Class IIIb/IV by 6 months, with sustained improvement of 80% through two years (P<0.0001).1

 

SIGNIFICANT INCREASE IN 6-MINUTE WALK DISTANCE

Before receiving the device, patients were able to walk an average of 136 meters in six minutes. Twenty-four months after receiving the HeartMate 3 LVAD, patients were able to walk an average of 323 meters in six minutes. That’s more than two times farther in distance.

 

 

MEANINGFUL IMPROVEMENT IN QUALITY OF LIFE1
 

SEE HOW A HEARTMATE 3™ LVAD CAN MAKE A DIFFERENCE IN YOUR PATIENTS LIVES

Jan has a long history of heart disease. Everything was well under control until 3 years ago when things started going downhill very fast. Discover how the HeartMate 3™ LVAD helped him to regain his quality of life and play with his grandchildren again.

Bob had nothing to lose, he wouldn’t live for very long without an LVAD. Discover how HeartMate 3™ LVAD gave Bob his life back.

Aiste was living an active life when she realized something wasn’t right. Her cardiologist understood an LVAD was Aiste’s only option while waiting for a heart transplant. Watch Aiste’s story and discover how the HeartMate 3™ LVAD is helping her to return to a more social life.

NEJM CLINICAL PAPER

Read the details of the clinical study as published in The New England Journal of Medicine.

BUILDING COMPREHENSIVE HEART FAILURE MANAGEMENT

The HeartMate 3™ LVAD is part of our heart failure management portfolio. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.

REFERENCES

* HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.

** For a continuous-flow LVAD in a randomized controlled trial.

*** Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

1. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. The New England journal of medicine. 2019;380:1618-1627. doi:10.1056/NEJMoa1900486. 

2. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, ... Gregoric ID. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-460. 

3. Starling RC, Estep JD, Horstmanshof DA, et al; ROADMAP Study Investigators (2017). Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. J Am Coll Cardio HF. 2017;5:518-27 

4. Jorde, UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardio. 2014;63:1751-7. 

5. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.

MAT-1900427 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO